Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the α5β1 integrin

Cell Adhesion and Migration

Volumn 11, Issue 4, 2017, Pages 305-315

  Joshi, Raghav ^a   Goihberg, Edi ^a   Ren, Wenying ^a   Pilichowska, Monika ^a   Mathew, Paul ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

adhesion; bone marrow mesenchymal stromal cells; bone metastases; chemotaxis; fibronectin fragments; matrikine; prostate cancer

Indexed keywords

CHEMOTACTIC FACTOR; FIBRONECTIN; PEPTIDE FRAGMENT; PROTEOME; SHORT HAIRPIN RNA; THROMBOSPONDIN 1; VERY LATE ACTIVATION ANTIGEN 5; HEPARIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING AFFINITY; BMSC CELL LINE; CELL ADHESION ASSAY; CELL COUNT; CELL INTERACTION; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CHEMOTAXIS; COCULTURE; CONDITIONED MEDIUM; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO GENE TRANSFER; MASS SPECTROMETRY; PROSTATE CANCER CELL LINE; PROTEIN PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; WESTERN BLOTTING; BONE; CELL ADHESION; MALE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROTEIN DEGRADATION; PROTEOMICS; SECRETION (PROCESS); TUMOR CELL LINE; TUMOR INVASION;

BONE AND BONES; CELL ADHESION; CELL LINE, TUMOR; CHEMOTAXIS; CHROMATOGRAPHY, AFFINITY; COCULTURE TECHNIQUES; FIBRONECTINS; HEPARIN; HUMANS; INTEGRIN ALPHA5BETA1; MALE; MESENCHYMAL STROMAL CELLS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEOLYSIS; PROTEOME; PROTEOMICS; THROMBOSPONDIN 1;

EID: 84981554902     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.1080/19336918.2016.1212139     Document Type: Article

References (41)

1. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases:targeting the lethal phenotype. J Clin Oncol 2005; 23:8232-41; PMID:16278478; https://doi.org/10.1200/JCO.2005.03.0841
2. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-23; PMID:23863050; https://doi.org/10.1056/NEJMoa1213755
3. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases:results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15:738-46; PMID:24836273; https://doi.org/10.1016/S1470-2045(14)70183-4
4. Boulais PE, Frenette PS. Making sense of hematopoietic stem cell niches. Blood 2015; 125:2621-9; PMID:25762174; https://doi.org/10.1182/blood-2014-09-570192
5. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841-6; PMID:14574413; https://doi.org/10.1038/nature02040
6. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466:829-34; PMID:20703299; https://doi.org/10.1038/nature09262
7. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004; 103:3258-64; PMID:14726388; https://doi.org/10.1182/blood-2003-11-4011
8. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Investig 2011; 121:1298-312; PMID:21436587; https://doi.org/10.1172/JCI43414
9. Margossian SS, Lawler JW, Slayter HS. Physical characterization of platelet thrombospondin. J Biol Chem 1981; 256:7495-500; PMID:7251605
10. Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays 1996; 18:71-6; PMID:8593167; https://doi.org/10.1002/bies.950180113
11. Resovi A, Pinessi D, Chiorino G, Taraboletti G. Current understanding of the thrombospondin-1 interactome. Matrix Biol 2014; 37:83-91; PMID:24476925; https://doi.org/10.1016/j.matbio.2014.01.012
12. Lawler J, Derick LH, Connolly JE, Chen JH, Chao FC. The structure of human platelet thrombospondin. J Biol Chem 1985; 260:3762-72; PMID:2579080
13. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002; 115:3861-3; PMID:12244123; https://doi.org/10.1242/jcs.00059
14. Dardik R, Lahav J. Multiple domains are involved in the interaction of endothelial cell thrombospondin with fibronectin. Eur J Biochem 1989; 185:581-8; PMID:2512126; https://doi.org/10.1111/j.1432-1033.1989.tb15153.x
15. Dreyfus M, Lahav J. The build-up of the thrombospondin extracellular matrix. An apparent dependence on synthesis and on preformed fibrillar matrix. Eur J Cell Biol 1988; 47:275-82; PMID:3072202
16. Homandberg GA, Kramer-Bjerke J. Thrombospondin binds to amino-terminal fragments of plasma fibronectin. Thromb Res 1987; 48:329-35; PMID:3433257; https://doi.org/10.1016/0049-3848(87)90445-2
17. Ricard-Blum S, Salza R. Matricryptins and matrikines:biologically active fragments of the extracellular matrix. Exp Dermatol 2014; 23:457-63; PMID:24815015; https://doi.org/10.1111/exd.12435
18. Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P. Fibronectin distribution in human bone marrow stroma:matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 1997; 230:111-20; PMID:9013713; https://doi.org/10.1006/excr.1996.3405
19. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmüller G, Pantel K. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors:establishment of working models for human micrometastases. Cancer Res 1999; 59:241-8; PMID:9892213
20. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci U S A 1993; 90:9374-8; PMID:7692447; https://doi.org/10.1073/pnas.90.20.9374
21. Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther 2012; 12:251-7; PMID:22192080; https://doi.org/10.1517/14712598.2012.646985
22. Bell-McGuinn KM, Matthews CM, Ho SN, et al. A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 2011; 121:273-9; PMID:21276608; https://doi.org/10.1016/j.ygyno.2010.12.362
23. Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2013; 24:90-6; PMID:22904239; https://doi.org/10.1093/annonc/mds281
24. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin:a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008; 14:7924-9; PMID:19047123; https://doi.org/10.1158/1078-0432.CCR-08-0378
25. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia (New York, NY) 2002; 4:191-4; https://doi.org/10.1038/sj.neo.7900224
26. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007; 67:61-73; PMID:17034033; https://doi.org/10.1002/pros.20500
27. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients:a randomized phase II trial by the prostate cancer clinical trials consortium. Investig New Drugs 2011; 29:1432-40; PMID:20336348; https://doi.org/10.1007/s10637-010-9420-8
28. Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K. Differential Effect on Bone Lesions of Targeting Integrins:Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 2016; 22(13):3192–200.
29. Zhang Z, Morla AO, Vuori K, Bauer JS, Juliano RL, Ruoslahti E. The alpha v beta 1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J Cell Biol 1993; 122:235-42; PMID:8314844; https://doi.org/10.1083/jcb.122.1.235
30. Veine DM, Yao H, Stafford DR, Fay KS, Livant DL. A D-amino acid containing peptide as a potent, noncovalent inhibitor of alpha5beta1 integrin in human prostate cancer invasion and lung colonization. Clin Exp Metastasis 2014; 31:379-93; PMID:24464034; https://doi.org/10.1007/s10585-013-9634-1
31. Schaffner F, Ray AM, Dontenwill M. Integrin alpha5beta1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers (Basel) 2013; 5:27-47; PMID:24216697; https://doi.org/10.3390/cancers5010027
32. Rosenberg A, Mathew P. Imatinib and prostate cancer:lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 2013; 22:787-94; PMID:23540855; https://doi.org/10.1517/13543784.2013.787409
33. Thibaudeau L, Holzapfel BM, Hutmacher DW. Humanized mice models for primary bone tumor and bone metastasis research. Cell cycle (Georgetown, Tex) 2015; 14:2191-2; PMID:26125650; https://doi.org/10.1080/15384101.2015.1062327
34. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999; 59:1987-93; PMID:10213511
35. Kuperwasser C, Dessain S, Bierbaum BE, et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res 2005; 65:6130-8; PMID:16024614; https://doi.org/10.1158/0008-5472.CAN-04-1408
36. Seib FP, Berry JE, Shiozawa Y, Taichman RS, Kaplan DL. Tissue engineering a surrogate niche for metastatic cancer cells. Biomaterials 2015; 51:313-9; PMID:25771021; https://doi.org/10.1016/j.biomaterials.2015.01.076
37. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012; 26:34-53; PMID:21886173; https://doi.org/10.1038/leu.2011.197
38. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-7; PMID:16923606; https://doi.org/10.1080/14653240600855905
39. Chen MS, Almeida EA, Huovila AP, Takahashi Y, Shaw LM, Mercurio AM, White JM. Evidence that distinct states of the integrin alpha6beta1 interact with laminin and an ADAM. J Cell Biol 1999; 144:549-61; PMID:9971748; https://doi.org/10.1083/jcb.144.3.549
40. Kudirka JC, Panupinthu N, Tesseyman MA, Dixon SJ, Bernier SM. P2Y nucleotide receptor signaling through MAPK/ERK is regulated by extracellular matrix:involvement of beta3 integrins. J Cell Physiol 2007; 213:54-64; PMID:17620283; https://doi.org/10.1002/jcp.21087
41. Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jäggle CS, Moyano JM, Kreysch HG, Piulats J, Goodman SL. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108(Pt 8):2825-38; PMID:7593323